COVID-19 Disease in Children With ALL Receiving Maintenance Therapy: Do Not Discount the Risk We conducted a two-round modified Delphi survey. Participants were patients (or their carers) who had ...
PHOENIX — Patients treated for cancer with immune checkpoint inhibitors (ICIs) who develop the drugs’ known side effects of diarrhea and colitis experience increased risk of adenomas in the colon — ...
Bottom Line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to ...
Checkpoint inhibitor-based therapy and ISRT may replace autologous transplant and high-dose chemotherapy in low-risk relapsed cHL, reducing side effects while maintaining EFS outcomes. The CheckMate ...
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon ...
Among propensity-matched cohorts, 17% of patients with metastatic lung cancer who received ICIs developed a pulmonary embolism within 1 year of beginning treatment, compared with 14.6% of those who ...
PD-1 and PD-L1 inhibitors are types of immune checkpoint inhibitors, which are immunotherapy medications for treating cancer. Immunotherapy helps the immune system find and kill cancer cells. Some ...
Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...
Bria-IMT combined with a checkpoint inhibitor improved overall survival in metastatic breast cancer compared to Trodelvy and chemotherapy. In triple-negative breast cancer, Bria-IMT showed a median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results